Health EquityRegulatory News Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancerA kit for at-home unsupervised self-collection clears FDA finish line April 17, 2026Vol.52 No.15By Claire Marie Porter
Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” April 17, 2026Vol.52 No.15By Jacquelyn Cobb
Cancer History ProjectEditorial Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budgetFox Chase’s Winn contemplates Crossroads 2.0 April 17, 2026Vol.52 No.15By Paul Goldberg
Guest Editorial Most Favored Nation drug pricing could put China on top April 17, 2026Vol.52 No.15By John Stanford
Cancer Policy FDA adds stereotactic breast biopsy needles to the shortage list April 17, 2026Vol.52 No.15By Jacquelyn Cobb
Cancer Policy CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans April 17, 2026Vol.52 No.15By Jacquelyn Cobb
Cancer Policy At Friends meeting, data quality, modern evidence generation, and early regulatory alignment top the list of “next steps” for external control arms April 17, 2026Vol.52 No.15By Jacquelyn Cobb
Cancer Policy ACIP charter is renewed as meetings remain on indefinite hold April 17, 2026Vol.52 No.15By Jacquelyn Cobb
Cancer Policy FDA issues reminder to sponsors: Disclose clinical trial results April 17, 2026Vol.52 No.15By Jacquelyn Cobb
Cancer Policy Health groups urge Bhattacharya, in his position of acting CDC director, to restore staff in the Office on Smoking and Health April 17, 2026Vol.52 No.15By Jacquelyn Cobb
